TG盗号软件免杀技术破解技术|【唯一TG:@heimifeng8】|电报盗号系统破解✨谷歌搜索留痕排名,史上最强SEO技术,20年谷歌SEO经验大佬✨Vaccine use reduces mortality from cervical cancer, study finds
According to a study published in the journal JAMA, mortality from cervical cancer has decreased among young women by 62 percent in recent decades, and this is explained by the use of respective vaccines since 2006. Dr. Ashish Deshmukh, the author of this study, emphasized that no other factor can explain such a considerable decrease.
Human papillomavirus (HPV) is the cause of almost all cases of cervical cancer. The aforesaid vaccine was intended for teenagers, but later its effect was also extended to people up to 45 years old, Focus reports. Previous studies have shown that the cases of cervical cancer have decreased, and they attribute it to this vaccine.
Focusing on women younger than 25, the researchers assessed the vaccine's early impact, and noted that those vaccinated between 2006 and 2025 were young enough to avoid cervical cancer deaths. From 2025 to 2025, this mortality decreased from 50 to 60 cases to just thirteen.
Despite this success, vaccination rates remain below target levels. The national goal is 80 percent enrollment of 13- to 15-year-olds by 2030—but according to current US Centers for Disease Control and Prevention (CDC) estimates, enrollment is only 60 percent. The Covid pandemic has contributed to a drop in HPV vaccination rates, and this has raised concerns about increased mortality.
A World Health Organization study highlights the wider global impact of HPV vaccines, and estimates the potential prevention of more than 60 million cases of cervical cancer in the coming decades if vaccination rates increase. This underscores the importance of health initiatives aimed at increasing vaccination enrolment to assist the downward trend in cervical cancer mortality.